| Literature DB >> 31680868 |
Tatyana Veremeyko1, Amanda W Y Yung1, Marina Dukhinova1,2, Tatyana Strekalova3,4,5, Eugene D Ponomarev1,6.
Abstract
Twenty years ago, the scientific community exhibited relatively little interest in the study of microglial cells. However, recent technical and conceptual advances in this field have greatly increased interest in the basic biology of these cells within various neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and traumatic brain/spinal cord injuries. The main functions of these cells in the normal central nervous system (CNS) remain poorly understood, despite considerable elucidation of their roles in pathological conditions. Microglia populate the brain before birth and remain in close lifelong contact with CNS-resident cells under the influence of the local microenvironment. Within the CNS parenchyma, microglia actively interact with two main cell types, astrocytes and neurons, which produce many factors that affect microglia phenotypes in the normal CNS and during neuroinflammation. These factors include interleukin (IL)-34, macrophage colony-stimulating factor, transforming growth factor-β, and IL-4, which promote microglial expansion, survival, and differentiation to an anti-inflammatory phenotype in the normal CNS. Under inflammatory conditions, however, astrocytes produce several pro-inflammatory factors that contribute to microglial activation. The interactions of microglia with neurons in the normal and diseased CNS are especially intriguing. Microglia are known to interact actively with neurons by facilitating axonal pruning during development, while neurons provide specific factors that alter microglial phenotypes and functions. This review focuses mainly on the roles of soluble neuronal factors that affect microglial phenotypes and functions and the possible involvement of these factors in the pathology of neurodegenerative diseases.Entities:
Keywords: microRNA; microglia; neuroinflammation; neurons; transcriptional regulation
Year: 2019 PMID: 31680868 PMCID: PMC6798237 DOI: 10.3389/fncel.2019.00453
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
FIGURE 1Comparison of expression of factors of chromatin remodeling BAF complexes at the stage of embryonic stems cells (esBAF), neuronal progenitor cells (npBAF), and neurons (nBAF) as well as analysis of expression neuronal genes in microglia, bone marrow-derived macrophages, peritoneal macrophages, and cultured cortical neurons. (A) Schematic diagram of Brm/Brg-associated factor (BAF) chromatin remodeling complex for three stages of neuronal differentiation from embryonic stem cells (ESC) to neuronal progenitor cells (NPC) and to mature neurons (Neuron) (Adapted from “Epigenetic regulation of neural differentiation from embryonic stem cells” by Atsushi Shimomura and Eri Hashino with permission. 2013 Shimomura A., Hashino E. Published in Trends in Cell Signaling Pathways in Neuronal Fate Decision under CC BY 3.0 license. Available from: 10.5772/53650). (B–G) Expression of factors of BAF complex BAF53A (B), BAF45A (C), BAF53B (D), SMARCC1 (E), SMARCC2 (F), and BAF45B (G) in microglia (MG), bone marrow-derived macrophages (BMDM), peritoneal macrophages (PM), and cultured cortical neurons (N). (H) Expression of neuronal genes BEX, SYT1, MAP2, and TUBB3 in microglia (MG), bone marrow-derived macrophages (BMDF), peritoneal macrophages (PM), and cultured cortical neurons (N).
Neuron-derived soluble factors that affect the activation state of microglia in normal CNS and during neuroinflammation and neurodegeneration.
| Cytokines | IL-4 | Decreased | Promote anti-inflammatory phenotype and expression of: Ym1, Fizz1, TGFβ1 ( |
| TGFβ1 | Decreased | Promote homeostatic phenotype of microglia in normal adult CNS ( | |
| IL-34 | Increased | Homeostatic maintenance, proliferation, and survival of microglia ( | |
| Chemokines | CCL2 | Increased | Microglia migration, activation, and proliferation ( |
| CXCL12 | Increased | Microglia migration and activation ( | |
| CX3CL1 (soluble form) | Decreased | Deactivate microglia ( | |
| Growth Factors | NGF | Increased | Promote anti-inflammatory phenotype of microglia ( |
| BDNF | Increased | Suppress release of NO in microglia. Promote anti-inflammatory phenotype ( | |
| Neurotransmitters | Serotonin (5HT) | Decreased during TBI-induced neuroinflammation | Decreased IFNγ-induced activation of macrophages and possibly microglia ( |
| Dopamine | Decreased | Possibly suppress microglia activation via DR2 ( | |
| Glutamate | Decreased | Promote microglia activation and expression of TNF and NO ( | |
| GABA | Decreased | Inhibit microglia activation and release LPS-induced TNF and IL-6 ( | |
| Low-molecular-weight mediators | ATP | Increased | Activate microglia ( |
| microRNAs | miR-124 miR-9 | Decreased Decreased | Deactivate microglia ( |
| Complement | C3 | Increased | Mediate synaptic pruning by microglia ( |
| C1q | Increased |
FIGURE 2Neuronal soluble factors that determine the ultimate phenotype of microglia in the normal or diseased CNS.